Physician profile
Steven A Ender
NPI 1609875657
$17,828.91
in general payments reported to CMS, 2019-2025
54 companies · $2,826 in 2025
The $2,826 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,915 · 2020: $1,866 · 2021: $2,988 · 2022: $3,535 · 2023: $2,306 · 2024: $2,393 · 2025: $2,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,413 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,413.19 |
| Education | $111.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,769.49 | 2021-2025 | |
| Biogen, INC. | $1,328.82 | 2019-2025 | Vumerity, Plegridy |
| Teva Pharmaceuticals USA, INC. | $1,265.26 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Ucb, INC. | $1,235.56 | 2019-2025 | Rystiggo, Briviact |
| Allergan, INC. | $1,083.60 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $822.66 | 2019-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $768.67 | 2020-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $750.77 | 2019-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $617.66 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $603.17 | 2022 | |
| Eisai INC. | $579.71 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $562.75 | 2019-2025 | Nuplazid |
| Argenx US, INC. | $495.66 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Amneal Pharmaceuticals LLC | $462.84 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Amgen INC. | $426.24 | 2019-2025 | Uplizna |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.